Disruptive Investor
Long/short equity, deep value, event-driven, macro

Medifast: Steep Growth Target Can Be Company's Undoing

Medifast (NYSE:MED), which primarily engages in the production, distribution, and sale of weight loss products, has set an optimistic revenue target of $1 billion by 2017 from FY12 revenue of $357 million. Achievement of the target growth would imply revenue CAGR of 23% over the next five years. This investment note discusses the possibility of achieving this target considering the company's growth strategy and its implications for the company's stock. Based on the arguments presented below, I am of the opinion that the company will disappoint on the growth front and the stock will be a victim of over optimism.

Talking about over optimism, Weight Watchers International (NYSE:WTW), another company that provides weight management services, slumped...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details